Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Placebo-controlled, Randomized, Sequential, Parallel-group, Dose Escalation Study to Evaluate 28-day Multiple Dose Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CP-690,550 in Stable Renal Allograft Recipients

NCT01710033 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01710033
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01710033 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Placebo-controlled, Randomized, Sequential, Parallel-group, Dose Escalation Study to Evaluate 28-day Multiple Dose Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CP-690,550 in Stable Renal Allograft Recipients
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2003
Completion date
April 30, 2005
Enrollment
28 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

kidney transplant